Given that all patients enrolled in our study were primarily diagnosed as NSCLC without any additional therapy, the positive results of EGFR mutation (87 patients), ALK rearrangement (8 patients), ROS1 rearrangement (1 patient), BRAF V600E mutation (1 patient), and METex14 skipping mutation (1 patient) have provided great guidance to help these patients with individually targeted medications. This evidence concerns the gene BRAF and non-small cell lung carcinoma.